Greenwich LifeSciences (GLSI) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Sionna Therapeutics (SION) over the past year, gaining 37.0% versus a loss of 83.2%. Greenwich LifeSciences is the larger company by market cap ($216.3 million vs $215.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | SION |
|---|---|---|
| Share price | $14.74 | $4.78 |
| Market cap | $216.28M | $215.82M |
| 1-day change | -4.26% | -0.83% |
| YTD return | -26.75% | -88.28% |
| 1-year return | +37.04% | -83.15% |
| 5-year return | -59.46% | — |
| EPS (TTM) | $-1.53 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $54.97 |
| 52-week low | $7.78 | $4.01 |
| Distance from 52-week high | -56.79% | -91.30% |
| Analyst consensus | none | hold |
| Avg. price target upside | +286.83% | +339.33% |
| Average volume | 138.72K | 2.19M |
| Shares outstanding | 14.68M | 45.15M |
| Employees | — | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed SION by 120.2 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
GLSI vs SION FAQ
Which is bigger, Greenwich LifeSciences or Sionna Therapeutics?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $216.28M compared with $215.82M for Sionna Therapeutics (SION).
Which stock has performed better over the past year, GLSI or SION?
GLSI returned +37.04% over the past 12 months, compared with -83.15% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.